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The Dutch virus-typing network VIRO-TypeNed reported 
an increase in ECHOvirus 6 (E-6) infections with neuro-
logical symptoms in the Netherlands between June and 
August 2016. Of the 31 cases detected from January 
through August 2016, 15 presented with neurological 
symptoms. Ten of 15 neurological cases were detected 
in the same province and the identified viruses were 
genetically related. This report is to alert medical and 
public health professionals of the circulation of E-6 
associated with neurological symptoms.
From June 2016 onwards, an increase in the number of 
ECHOvirus 6 (E-6) infections was noted by the Dutch 
virus-typing network VIRO-TypeNed [1]. Among a total 
of 31 cases, 15 presented with neurological symptoms. 
Compared with the annual average of four cases with 
a neurological E-6 infection in the past five years, this 
increase was statistically significant. Here we aim to 
alert medical and public health professionals of the 
increase and circulation of E-6 associated with neuro-
logical symptoms.
Epidemiological investigation
In the period from January to August 2016, 242 enter-
ovirus (EV) cases were reported by VIRO-TypeNed 
[1]. E-6 was the most frequently identified type and 
accounted for 13% (n = 31) of the EV cases; in previous 
years, this type had only been detected in on average 
4% of the cases, ranging from 0.3% (1/308) in 2010 to 
6% (26/464) in 2015. The female:male ratio among E-6 
cases was 1:1 and 18 of the 31 cases were younger than 
seven years (range: 2 weeks–44 years).
44 (18%) of the total 242 EV cases presented with 
neurological symptoms and 15 of them were infected 
with E-6 (Figure 1, Table). Cases that presented with 
neurological symptoms were defined as patients with 
aseptic meningitis (n = 4), suspected or undefined neu-
rological presentation (n = 2) or an (unreported) clinical 
presentation that prompted the physician to examine 
the cerebrospinal fluid (CSF) (n = 9).
The total number of cases (irrespective of EV type) pre-
senting with neurological symptoms was not increased 
compared with the respective period (January through 
August) in the previous five years: the average in this 
period was 41 cases, ranging from 24 in 2013 to 50 in 
2014. However, in 2016, the proportion of E-6 cases 
with neurological symptoms was significantly higher 
compared with other EV types with neurological symp-
toms (p value < 0.05 based on the univariable chi-
squared test) (Table). Specifically, the number of cases 
with neurological symptoms was not increased for any 
of the other top five detected types (Coxsackievirus 
(CV)-B3, CV-B5, EV-A71 and CV-A6) (Table).
The 31 E-6 cases detected since January 2016 were 
identified across the Netherlands. However, from 
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June through August 2016, when EV infections asso-
ciated with neurological symptoms peaked, a cluster 
of 10 cases infected with the same E-6 strain were 
found to reside in the same province (6 female and 4 
male cases, median age: 27 years; range: 2 weeks–45 
years). Nine of those cases presented with neurologi-
cal symptoms and included seven adults (median: 28 
years; range: 27–45). Five of the 10 cases resided in 
the same municipality and four of them were neurolog-
ical cases. These five cases included a two-week-old 
neonate and its mother. The child had a fever, without 
evident neurological symptoms. Further investigations 
are being conducted on the clinical and epidemiologi-
cal characteristics of the cases in the cluster to investi-
gate a possible source and link. In the same province, 
36 EV cases were detected in total and clinical infor-
mation was available for all; of the 26 cases infected 
with strains other than E-6, only six presented with 
neurological symptoms; they were infected with CV-B5 
(n = 2), CV-B3 (n = 1), E-7 (n = 1), E-18 (n = 1) and E-30 
(n = 1).
Phylogenetic investigation 
In the phylogenetic analysis based on the partial VP1 
region [2], the E-6 strains circulating in the Netherlands 
since 2010 could be grouped in the previously assigned 
genogroups B (one strain from 2015), C1 (75 strains 
from 2011–16), C4 (two strains from 2014) and C9 (65 
strains from 2010–16) [3,4]. Twenty-eight of the 31 E-6 
strains recovered in 2016, including those from the 
provincial cluster, could be characterised as C1 (Figure 
2), and the three remaining strains as C9. The strains 
from the cluster were 99.9% homologous.
Outbreak detection and response
EV infection is not notifiable in the Netherlands, but 
more than 300 EV per year are typed in the poliovirus 
exclusion and EV surveillance programme. Here, we 
detected the outbreak in a timely manner through our 
regular analysis of data in the VIRO-TypeNed database, 
observing 10 cases in one province that clustered in 
time and place and had identical molecular types. The 
cluster was reported to the national early warning com-
mittee and surveillance unit of the national institute for 
public health and the environment (RIVM) in order to 
alert and create awareness among medical and public 
health professionals.
Background
E-6 is one of the five most frequently detected EV types 
associated with neurological symptoms worldwide, 
next to EV-A71, E-11, E-30 and CV-B5, each accounting 
for 15–20% of EV types identified in a year [5-10]. EVs 
are ubiquitous and circulate all year round with peaks 
in the summer months. Neurological symptoms can 
be linked to various types. However, there have been 
years where a majority of neurological cases could be 
linked to a specific type ([5-10] and data not shown), as 
is currently seen for E-6 in 2016. E-6 is endemic in the 
Netherlands and was detected more frequently in 2000 
and 2009 by the clinical surveillance as described by 
van der Sanden et al. (Figure 3) [11].
Typing of positive isolates from clinical surveillance is 
primarily performed to exclude the circulation of polio-
virus [11]. The data on non-Polio EV (NPEV) types are 
used to monitor NPEV circulation and trends in NPEV 
illness. Since 2010, these data have been collected 
in a standardised manner through VIRO-TypeNed. 
VIRO-TypeNed is a virus-typing network using a joint 
data-sharing database for clinical and public health 
laboratories to provide a more complete surveillance 
of EV including genetic, epidemiological, patient and 
clinical data such as information on gastrointestinal, 
respiratory and neurological symptoms [1]. Details 
on the surveillance system (sampling method, detec-
tion and typing methods, reporting of data) have been 
described elsewhere [12]. In short, all EV-positive 
cases detected through real-time PCR that can be char-
acterised by partial typing of the VP1 region [2] include 
a minimum dataset including age and sex of patient, 
type of sample from which the virus was detected, 
whether the patient was hospitalised, travel history (by 
country visited) and clinical symptoms in broad cate-
gories (skin, neurological, respiratory, enteric). Cases 
presenting with neurological symptoms are defined 
as having aseptic meningitis, suspected or undefined 
neurological presentation, encephalitis, convulsions, 
or from whom clinical presentation (unreported) was 
such as to prompt the physician to examine the CSF.
Discussion
On 8 August, the European Centre for Disease 
Prevention and Control (ECDC) published a rapid risk 
assessment (RRA) regarding EV detections in severe 
Figure 1
Monthly distribution of neurological cases with 
enterovirus infection, reported by VIRO-TypeNed, the 
Netherlands, January–August 2016 (n = 44)
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Figure 2
Neighbour-joining (maximum composite likelihood) tree based on a 250 nt VP1 fragment [2] of ECHOvirus 6 from 
patients, the Netherlands, 2010–2016 (n = 31)
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neurological cases among children and adults in 
Europe, to reinforce vigilance for EV-associated neuro-
logical disease [13]. Several types were reported across 
Europe, and alerts were released on an increase in the 
number of EV-A71 (a new C1 variant) associated with 
neurological symptoms [13] as well as on an increase 
of EV-D68 associated with severe respiratory disease.
The E-6 increase represents the second EV signal in 
the Netherlands in 2016, following the EV-D68 increase 
seen in the summer of 2016 [13]. Both outbreaks were 
rapidly detected by the national VIRO-TypeNed surveil-
lance system [1]. As this system includes epidemiologi-
cal, clinical and molecular typing data, near real-time 
cluster detection is feasible. At the moment, outbreak 
detection is based on weekly analysis of the data in the 
VIRO-TypeNed database. As the majority of EV infec-
tions are asymptomatic and mild, not all infections 
are reported. Therefore, we cannot exclude that the 
increase is biased based on active reports of severe 
(neurological) cases. However, a comparison of the 
data with only severe (neurological) cases in previous 
years revealed a clear increase for E-6; A majority of 
these cases were defined based on unreported clini-
cal presentation where CSF was examined. The data on 
specimen type (CSF) is unbiased and completeness of 
this dataset is more than 90%.
Phylogenetic analysis suggested that the 2016 out-
break is associated with the C1 strain. Previous reports 
on E-6 outbreaks were related to C9, for example a 
major outbreak associated with neurological symptoms 
in Spain in 2008 [5] and in other countries since 2000 
[3]. Analysis of full-length VP1 or full-length genomes 
as well as serological studies are needed to further 
investigate the underlying genetical and immunological 
factors that are responsible for the possible increase 
in neurological virulence and/or possible increase in 
circulation (e.g. viral fitness, transmissibility or lack 
of immunity). Of interest is that while more than half 
of the E-6 cases seen nationwide occurred in children, 
most cases belonging to the cluster were older than 
27 years, suggesting that severity is not related to a 
younger age but rather to waning immunity or lack of 
immunity to the C1 strain.
Preventive measures for EV outbreaks are limited to 
advice on more stringent cough and hand hygiene or 
case isolation to prevent nosocomial spread. Treatment 
options for (severe) EV infections are limited. Based on 
the humoral responsiveness of EV infection, intrave-
nous IG (IVIG) can be given in severe cases. However, 
IVIG is not always effective [14]. While antiviral drugs 
against EV infections are under development, there is 
still no EV-specific treatment available [15,16]. Several 
studies have described the use of the capsid inhibitor 
pleconaril on a compassionate use basis in neonates 
and immunocompromised patients with severe EV 
infections, with variable outcome [14]. Other options 
are drugs marketed for other viral infections or clinical 
conditions that can be used off-label, however, they 
have never been clinically tested in EV cases and pub-
lic health implications are unknown [15].
Figure 3
Distribution of cases of ECHOvirus 6 infection, the Netherlands, 1996–2015 (clinical surveillance; n = 728) and 2010–2016 
(VIRO-TypeNed; n = 133)
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Table
Enterovirus types reported to VIRO-TypeNed with cases 
presenting with neurological symptoms, the Netherlands, 
January–August 2016 (n = 172a)
EV species EV type Number of cases
Number of cases 
with neurological 
symptoms
EV-A EV-A71b 20 (13 C2; 7 C1) 1
EV-B CV-A9 12 3
EV-B CV-B1 13 2
EV-B CV-B2 6 1
EV-B CV-B3b 20 3
EV-B CV-B4 12 2
EV-B CV-B5b 21 5
EV-B E-5 3 1
EV-B E-6b 31 15
EV-B E-7 6 1
EV-B E-9 4 1
EV-B E-13 10 4
EV-B E-18 2 1
EV-B E-30 12 4
CV: Coxsackievirus; E: ECHOvirus; EV: Enterovirus. 
a For types CV-A2 (n = 1), CV-A5 (n = 1), CV-A6b (n = 21), CV-A8 
(n = 2), CV-A10 (n = 8), CV-A13 (n = 1), CV-A14 (n = 1), CV-A16 
(n = 2), CV-A22 (n = 1), E-3 (n = 2), E-11 (n = 10), E-16 (n = 1), 
E-25 (n = 2) and EV-D68 (n = 17), no cases presenting with 
neurological symptoms were reported.
b EV types ranked top five detected types (January to August 2016).
Case definition of neurological cases: patients with aseptic 
meningitis, suspected or undefined neurological presentation, 
encephalitis, convulsions, or with a clinical presentation 
(not reported) that prompted the physician to examine the 
cerebrospinal fluid.
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